Biomarkers in Giant Cells Arteritis

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Kiungo kimehifadhiwa kwenye clipboard

HaliKuachishwa

Wadhamini

University Hospital, Grenoble

JARIBIO LA KLINIKI: NCT02844023

BioSeek: NCT02844023

Maneno muhimu

Kikemikali

Giant cells arteritis or Horton disease is a vasculitis that affects great vessels. This is the most frequent vasculitis of the population over the age of 50. This vasculitis is at the origin of an inflammatory infiltrate of arterial tunics, essentially composed of lymphocytes. Clinical signs are a deterioration of general state, unusual cephalgias, jaw pain, scalp hyperesthesia, but can also be serious ischemic complication, especially ophthalmologic with the possibility to go blind. Until now, the standard treatment is a high dosage corticosteroid therapy.

Diagnosis is based on criterias of the American College of Rheumatology, dating back to 1990. The relapse rate is important, ranging from 10 to 64 % according to studies. There are also issues of becoming dependent on steroid.

So it is important to determine new diagnosis markers and a therapeutic following of giant cells arteritis.

With this study several biomarkers of inflammation will be studied in order to determine if one ore many of them have a good sensitivity and special feature for diagnosis and following of giant cells arteritis.

The main goal is to determine a new diagnosis marker for giant cells arteritis.

Tarehe

Imethibitishwa Mwisho:	03/31/2019
Iliyowasilishwa Kwanza:	07/19/2016
Uandikishaji uliokadiriwa Uliwasilishwa:	07/21/2016
Iliyotumwa Kwanza:	07/25/2016
Sasisho la Mwisho Liliwasilishwa:	04/15/2019
Sasisho la Mwisho Lilichapishwa:	04/17/2019
Tarehe halisi ya kuanza kwa masomo:	12/31/2014
Tarehe ya Kukamilisha Msingi iliyokadiriwa:	01/13/2019
Tarehe ya Kukamilisha Utafiti:	01/13/2019

Hali au ugonjwa

Giant Cells Arteritis

Uingiliaji / matibabu

Behavioral: Patient with giant gells arteritis

Other: Patient with giant gells arteritis

Device: Patient with giant gells arteritis

Other: Patient with giant gells arteritis

Biological: Control patients

Awamu

Vikundi vya Arm

Mkono	Uingiliaji / matibabu
Other: Patient with giant gells arteritis 50 patients with giant gells arteritis	Behavioral: Patient with giant gells arteritis With questionnaire.
Other: Control patients 50 control patients : blood from French national blood service (EFS)	Biological: Control patients Control patients.

Vigezo vya Kustahiki

Jinsia Inastahiki Kujifunza

All

Hupokea Wajitolea wa Afya

Ndio

Vigezo

Inclusion Criteria:

- Patient suffering from giant cells arteritis.

- Inclusion while discovery of symptoms, or during relapse.

Exclusion Criteria:

- Healthy volunteer

- Treatment with corticosteroid since more than 8 days for a patient suffering from giant cells arteritis, exept for patients under corticosteroid for a polymyalgia rheumatica.

- Other diseases than giant cells arteritis that could introduce an inflammatory symptom, especially a tumoral process in progress or a chronic inflammatory disease (any other one than giant cells arteritis)

Matokeo

Hatua za Matokeo ya Msingi

1. Biomarkers's serum sampling [3 minutes]

For dosage of biomarkers in serum, like serum amyloid A or interleukins.

Biomarkers in Giant Cells Arteritis

Maneno muhimu

maumivu ya kichwa

inflammation

atrophy

giant cell arteritis

hyperesthesia

arteritis

vasculitis

antifungal